High-dose bevacizumab for radiation-induced brain necrosis: a case report

Radiation-induced brain necrosis (RIBN) is a common adverse event from radiation therapy. We present a case of a 56-year-old man, diagnosed with non-small-cell lung cancer with brain metastases 2 years prior, for which he had received whole brain radiotherapy and brain stereotactic radiosurgery, who presented to the oncology unit with headache, dizziness and abnormal gait. MRI of the brain revealed radiological worsening of a cerebellar mass, including edema and mass effect. After a multidisciplinary tumor board meeting, the patient was diagnosed with RIBN and received 4 cycles of high-dose bevacizumab, with complete symptom resolution and significant radiological response. We report the successful use of a high-dose, shorter-duration treatment protocol of bevacizumab for RIBN.

[1]  M. Lawton,et al.  Differentiating radiation necrosis from tumor recurrence: a systematic review and diagnostic meta-analysis comparing imaging modalities , 2023, Journal of Neuro-Oncology.

[2]  G. Barnett,et al.  Radiation necrosis or tumor progression? A review of the radiographic modalities used in the diagnosis of cerebral radiation necrosis , 2023, Journal of Neuro-Oncology.

[3]  Tao Huang,et al.  Distinguishing Tumor Recurrence From Radiation Necrosis in Treated Glioblastoma Using Multiparametric MRI. , 2021, Academic radiology.

[4]  A. Sloan,et al.  Radiation Necrosis from Stereotactic Radiosurgery—How Do We Mitigate? , 2021, Current Treatment Options in Oncology.

[5]  Guixiang Liao,et al.  Bevacizumab Treatment of Radiation-Induced Brain Necrosis: A Systematic Review , 2021, Frontiers in Oncology.

[6]  N. Lin,et al.  Management of brain metastases according to molecular subtypes , 2020, Nature Reviews Neurology.

[7]  C. Anders,et al.  Current multidisciplinary management of brain metastases , 2020, Cancer.

[8]  H. Inoue,et al.  Effect of bevacizumab on brain radiation necrosis in anaplastic lymphoma kinase‐positive lung cancer , 2019, Respirology case reports.

[9]  N. Tandon,et al.  Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities , 2019, Current Oncology Reports.

[10]  D. Reardon,et al.  Efficacy and safety of immune checkpoint blockade for brain metastases , 2019, CNS oncology.

[11]  Joe Y. Chang,et al.  Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues , 2019, Molecular Cancer.

[12]  S. Lo,et al.  Diagnosis and Management of Radiation Necrosis in Patients With Brain Metastases , 2018, Front. Oncol..

[13]  C. Bettegowda,et al.  Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.

[14]  David Moher,et al.  CARE guidelines for case reports: explanation and elaboration document. , 2017, Journal of clinical epidemiology.

[15]  Jennifer S. Yu,et al.  Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. , 2016, International journal of radiation oncology, biology, physics.

[16]  S. Miyatake,et al.  Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain , 2014, Neurologia medico-chirurgica.

[17]  M. Gilbert,et al.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. , 2011, International journal of radiation oncology, biology, physics.

[18]  Hong Liu,et al.  Multivoxel 3D proton MR spectroscopy in the distinction of recurrent glioma from radiation injury , 2007, Journal of Neuro-Oncology.

[19]  S. Keam,et al.  Bevacizumab: a review of its use in metastatic colorectal cancer. , 2008, Drugs.